m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02865)
Name
Imisopasem manganese
Synonyms
KM-4403; M-40403; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis); Imisopasem manganese (dermatological,psoriasis/atopic dermatitis), ActivBiotics; Imisopasem manganese (dermatological, psoriasis/atopic dermatitis), Metaphore; M-40403 (dermatological, psoriasis/atopic dermatitis), Metaphore
    Click to Show/Hide
Status
Phase 2
Structure
3D MOL
2D MOL
Formula
C21H35Cl2MnN5
InChI
1S/C21H35N5.2ClH.Mn/c1-3-10-20-18(8-1)22-12-13-23-19-9-2-4-11-21(19)25-15-17-7-5-6-16(26-17)14-24-20;;;/h5-7,18-25H,1-4,8-15H2;2*1H;/q;;;+2/p-2/t18-,19-,20-,21-;;;/m1.../s1
InChIKey
WXEMWBBXVXHEPU-XNPJUPKFSA-L
PubChem CID
6918487
TTD Drug ID
D00OYQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Superoxide dismutase Mn (SOD Mn)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Superoxide dismutase Mn (SOD Mn) is a therapeutic target for Imisopasem manganese. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Imisopasem manganese through regulating the expression of Superoxide dismutase Mn (SOD Mn). [1], [2]
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Superoxide dismutase Mn (SOD Mn) is a therapeutic target for Imisopasem manganese. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Imisopasem manganese through regulating the expression of Superoxide dismutase Mn (SOD Mn). [2], [3]
References
Ref 1 FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma. Cancer Gene Ther. 2022 Feb 10. doi: 10.1038/s41417-022-00429-6. Online ahead of print.
Ref 2 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 3 Genetic variants in N6-methyladenosine are associated with bladder cancer risk in the Chinese population. Arch Toxicol. 2021 Jan;95(1):299-309. doi: 10.1007/s00204-020-02911-2. Epub 2020 Sep 22.